|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:ARMO_Bio_Sciences
gptkb:Molecular_Templates
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:ceo
|
gptkb:H._Thomas_Watkins
|
|
gptkbp:clinical_trial
|
global presence
multiple ongoing
diverse pipeline
|
|
gptkbp:collaboration
|
academic institutions
research organizations
|
|
gptkbp:community_engagement
|
philanthropic initiatives
patient advocacy support
|
|
gptkbp:employees
|
approximately 1,500
|
|
gptkbp:financial_performance
|
consistent growth
|
|
gptkbp:focus
|
gptkb:cancer_treatment
autoimmune diseases
inflammation treatment
|
|
gptkbp:founded
|
gptkb:1991
|
|
gptkbp:founder
|
gptkb:David_R._Hyman
|
|
gptkbp:headcount
|
increased over the years
|
|
gptkbp:headquarters
|
gptkb:Wilmington,_Delaware
|
|
gptkbp:healthcare
|
oncology
rare diseases
hematology
dermatology
infectious diseases
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
INCY
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:invention
|
numerous granted patents
|
|
gptkbp:investment
|
strategic acquisitions
R& D investments
|
|
gptkbp:investment_strategy
|
publicly traded
NASDAQ listed
|
|
gptkbp:leadership
|
diverse leadership team
|
|
gptkbp:market_cap
|
$25 billion (2021)
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:Iclusig
gptkb:Jakafi
gptkb:Pemazyre
|
|
gptkbp:research_focus
|
biologics
small molecule drugs
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:stock_symbol
|
gptkb:INCY
|
|
gptkbp:sustainability
|
environmental initiatives
corporate responsibility programs
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.incyte.com
|
|
gptkbp:bfsParent
|
gptkb:Incyte_Corporation
|
|
gptkbp:bfsLayer
|
5
|